Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04136309 in chronic HCV infection
NCT01226797Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C (HCV) comparing PF-04136309 with Placebo (2 arms). Primary endpoint: Percentage of Participants With a Response in Serum Alanine Aminotransferase (ALT) Level at Week 4. Started Jan 2011; status: terminated.
02
Drugs
PF-04136309
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01226797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01226797.